ERBB2 and breast carcinoma: In a panel of breast cancer cell lines, we observed that the cancer cell lines with CA (mostly TNBC and HER2 + ) express higher levels of TACC3 and are more sensitive to TACC3 inhibition with BO-264 [21] (Fig. 1I–K).